Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol and risk of persistent pulmonary hypertension of the newborn
2024-515216-46-00Phase 4Completed
- Sponsor
- Medical University of Warsaw
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of salbutamol in No single canonical name; "breathing disorder" is a general, non-specific term, transient tachypnea of the newborn (TTN) and persistent pulmonary hypertension of the newborn (PPHN), sponsored by Medical University of Warsaw. Primary endpoint: Incidence of persistent pulmonary hypertension of the newborn (PPHN). Started Nov 2021; status: completed.
02
Drugs
salbutamol
03
Conditions
No single canonical name; "breathing disorder" is a general, non-specific term.transient tachypnea of the newborn (TTN)persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on 2024-515216-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515216-46-00.